Related Experiment Video

Updated: Jun 25, 2026

Cell Type-specific Gene Expression Profiling in the Mouse Liver
10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

Liver diseases related to MDR3 (ABCB4) gene deficiency

Emmanuel Gonzales1, Anne Davit-Spraul, Christiane Baussan

  • 1Pediatric Hepatology and National Reference Centre for Biliary Atresia, Bicêtre Hospital, University of Paris - South 11, AP-HP, Paris, France.

Frontiers in Bioscience (Landmark Edition)
|March 11, 2009
PubMed

Insights

Mutations in the MDR3 (ABCB4) gene cause severe liver disease by impairing bile phospholipid excretion. These defects predispose individuals to multiple liver conditions, with some patients potentially benefiting from targeted therapies.

Area of Science:

  • Hepatology
  • Genetics
  • Molecular Biology

Background:

  • Class III multidrug resistance P-glycoproteins, MDR3 (ABCB4) in humans, are crucial for biliary phospholipid excretion.
  • Defects in the MDR3 gene are linked to progressive familial intrahepatic cholestasis type 3 (PFIC3), a severe pediatric liver disease.

Purpose of the Study:

  • To investigate the role of MDR3 gene defects in various human liver diseases.
  • To understand the molecular mechanisms and clinical implications of MDR3 deficiency.

Main Methods:

  • Identification and analysis of MDR3 mutations in patients with liver diseases.
  • Assessment of canalicular MDR3 protein expression and function.
  • Correlation of genetic defects with clinical phenotypes and biliary parameters.

Main Results:

  • MDR3 mutations lead to reduced phospholipid levels in bile, increasing cholesterol saturation.
  • MDR3 defects result in loss of canalicular MDR3 protein and/or function.
  • Biallelic or monoallelic MDR3 defects are associated with six distinct liver diseases.

Conclusions:

  • MDR3 gene defects are implicated in a spectrum of liver diseases beyond PFIC3.
  • Understanding MDR3 function is critical for diagnosing and managing these cholestatic conditions.
  • Patients with MDR3 deficiency may respond to ursodeoxycholic acid and could be candidates for future cell or pharmacological therapies.

More Related Videos

Determining Bile Duct Density in the Mouse Liver07:35

Determining Bile Duct Density in the Mouse Liver

Published on: April 30, 2019

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...